Saturday, November 27, 2021
Home > HEALTH > Modern analysis: Those who were vaccinated last year are twice as likely to get COVID-19 than those who were recently vaccinated

Modern analysis: Those who were vaccinated last year are twice as likely to get COVID-19 than those who were recently vaccinated

Modern analysis: Those who were vaccinated last year are twice as likely to get COVID-19 than those who were recently vaccinated

Moderna Inc. has released a set of data suggesting that its COVID-19 vaccine is effective in preventing serious health problems or deaths from “variants of concern”, but admits that the effect decreases over time, so that those who received the vaccine last year were twice as likely to have a breakthrough case of coronavirus disease.

According to the data published by Moderna on Wednesday, a “study shows a lower risk of breakthrough infection in participants recently vaccinated (median 8 months after the first dose) than participants vaccinated last year (median 13 months after the first dose).”

COVID-19 kills Americans at a rate of 1 in 500, data show

A Moderna trial conducted over the summer, labeled Phase 3 COVE study, revealed that “88 breakthrough cases of COVID-19 occurred in the newer vaccinated group (49.0 cases per 1000 individuals) compared to 162 cases in the vaccinated group. last year (77.1 cases per 1000 man-years). “

Across both groups, Moderna highlighted that “only 19 serious cases were observed.” Although there was a “numerical trend towards a lower incidence of serious cases in the groups recently vaccinated.” Moderna insisted that the number of cases was low enough that the trend “was not significant.”

The study showed that those who were vaccinated earlier had a 50% higher rate of symptomatic breakthrough cases in July and August compared to those who had received the vaccination later.

CLICK HERE TO GET THE FOX NEWS APP

In a statement issued with the data, Moderna’s CEO St├ęphane Bancel insisted that the data “supports the need for a booster” shot.

“It is promising to see clinical and real-world evidence adding to the growing body of data on the efficacy of the Moderna COVID-19 vaccine,” Bancel said of the unpublished analysis. “The increased risk of breakthrough infections in participants in COVE studies vaccinated last year compared to recently illustrates the effect of declining immunity and supports the need for a booster to maintain a high level of protection.

Moderna has also requested permission from the U.S. Food and Drug Administration for a third-dose booster shot, which will be half the dose of the existing vaccine.

Leave a Reply

Your email address will not be published. Required fields are marked *